Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
November 14, 2024 16:15 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
November 13, 2024 12:22 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
November 12, 2024 16:45 ET | Cyclacel
BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
October 24, 2024 09:15 ET | Cyclacel
CYCLACEL PHARMACEUTICALS ANNOUNCES THAT NASDAQ GRANTED AN EXTENSION TO REGAIN COMPLIANCE WITH THE EQUITY STANDARD RULE
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
October 23, 2024 09:15 ET | Cyclacel
NEW CLINICAL DATA FROM ONGOING, PHASE 2 STUDY OF ORAL FADRACICLIB AT THE 2024 ENA SYMPOSIUM. Patients preselected for CDKN2A and/or CDKN2B abnormalities
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
October 09, 2024 09:15 ET | Cyclacel
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalities
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
September 25, 2024 09:15 ET | Cyclacel
Cyclacel announces completion of enrollment in the biomarker-enriched cohort of its Phase 2 study - Patients are preselected for C
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024 09:15 ET | Cyclacel
Cyclacel to participate at the H.C. Wainwright 26th Annual Global Investment Conference
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
September 03, 2024 09:15 ET | Cyclacel
Cyclacel timely appeals against Nasdaq delisting letter. Delisting stayed until Nasdaq hearing panel determination
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
August 14, 2024 16:05 ET | Cyclacel
Cyclacel provides Q2 2024 financial results and business update on fadraciclib precision medicine strategy